Version 1
: Received: 7 July 2023 / Approved: 7 July 2023 / Online: 10 July 2023 (11:08:54 CEST)
Version 2
: Received: 12 July 2023 / Approved: 12 July 2023 / Online: 13 July 2023 (10:07:32 CEST)
Version 3
: Received: 14 July 2023 / Approved: 17 July 2023 / Online: 17 July 2023 (13:22:33 CEST)
Motomura, K.; Kuwano, A.; Tanaka, K.; Koga, Y.; Masumoto, A.; Yada, M. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers2023, 15, 4345.
Motomura, K.; Kuwano, A.; Tanaka, K.; Koga, Y.; Masumoto, A.; Yada, M. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers 2023, 15, 4345.
Motomura, K.; Kuwano, A.; Tanaka, K.; Koga, Y.; Masumoto, A.; Yada, M. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers2023, 15, 4345.
Motomura, K.; Kuwano, A.; Tanaka, K.; Koga, Y.; Masumoto, A.; Yada, M. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers 2023, 15, 4345.
Abstract
A number of agents, including immune checkpoint inhibitors, have become available for the treatment of hepatocellular carcinoma (HCC). However, the objective response rate of these drugs is currently only 30% to 40%, with a high incidence of side effects. There are also no prac-tical biomarkers to predict their therapeutic effects. Most of the systemic therapies for HCC are performed in general hospitals without research facilities. Such hospitals can perform imaging tests, like CT and MRI, as well as pathological diagnosis using tumor tissue sampling and im-munohistochemical staining. However, analyzing tumor genomic or transcriptomic profiles is difficult because of limitations in facilities, personnel, and cost. Therefore, in this review, we provide an overview of the wide range of research that has been conducted on HCC biomarkers from blood, tissue, or imaging information that can be used practically in general hospitals for predicting the therapeutic effect of systemic therapies before treatment begins. For general hos-pitals that treat HCC patients, we recommend conducting treatment after assessing the state within the tumor tissue as much as possible by collecting blood and tissue samples and per-forming pre- treatment MRI image evaluations.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
17 July 2023
Commenter:
Kenta Motomura
Commenter's Conflict of Interests:
Author
Comment:
I made the following changes because the tables have been converted to landscape orientation: I reverted the abbreviated names of drugs back to their full names as much as possible. In the previous portrait-oriented table, the column width was narrow, and I had to connect terms with a hyphen due to line breaks, as in 'sora-fenib' or 'regora-fenib'. Now that we have more space with the landscape format, I've removed the hyphens. I changed the column name 'Agents' back to 'Therapeutics'.I added dotted and solid lines within the tables to make it easier to distinguish between cohorts and predictive factors. Some instances of 'et al.' after author names had disappeared, so I added those back in. I changed the line breaks in the 'Study Design' field to make it easier to read.
Commenter: Kenta Motomura
Commenter's Conflict of Interests: Author
I reverted the abbreviated names of drugs back to their full names as much as possible. In the previous portrait-oriented table, the column width was narrow, and I had to connect terms with a hyphen due to line breaks, as in 'sora-fenib' or 'regora-fenib'. Now that we have more space with the landscape format, I've removed the hyphens.
I changed the column name 'Agents' back to 'Therapeutics'.I added dotted and solid lines within the tables to make it easier to distinguish between cohorts and predictive factors.
Some instances of 'et al.' after author names had disappeared, so I added those back in.
I changed the line breaks in the 'Study Design' field to make it easier to read.